Abramovitch, A., Short, T., & Schweiger, A. (2021). The C Factor: Cognitive dysfunction as a transdiagnostic dimension in psychopathology. Clinical Psychology Review, 86, 1-17.
In order to determine whether cognitive deficiencies are an intrinsic triagnostic entity, this study undertakes a systematic analysis of meta-analyses that look at cognitive function. This study is a non-experimental systematic review that included 97 clinical samples from meta-analyses to examine the role of cognition in all diseases for which data were available. The following factors were noted: the publication year, the disorder category, the specifier/status, and the number of studies included in the meta-analysis. More variables include the total clinical and control samples, the name of the neuropsychological test, the outcome measures, the confidence interval, and information about heterogeneity. The demographics of the participants were not specified by the study, as it was focused on the existing meta-analyses. The findings are qualitative and show that all disorders examined are connected to poor performance across cognitive domains, which is evidence that the C factor is a transdiagnostic factor tied to p.
Chen, K. S., Dwivedi, Y., & Shelton, R. C. (2022). The effect of IV ketamine in patients with major depressive disorder and elevated features of borderline personality disorder. Journal of Affective Disorders, 315, 13-16.
The effectiveness of IV ketamine in the treatment of major depressive illness is examined in this paper. This study was experimental, correlational, and empirical in nature and involved the Borderline Subscale of the Personality Assessment Inventory (PAI) being used to evaluate 153 male and female adult patients ages 18–65 with MDD. Over the course of 40 minutes, patients received 0.5 mg/kg of ketamine IV. The Beck Depression Inventory-II was utilized to measure mood at baseline, three, and twenty-four hours after ketamine. These results are qualitative and suggest that both MDD patients showing high borderline characteristics and those who did not have them are responsive to IV ketamine.
Glasner‐Edwards, S., Mooney, L. J., Marinelli‐Casey, P., Hillhouse, M., Ang, A., Rawson, R. A., & Methamphetamine Treatment Project Corporate Authors. (2010). Psychopathology in methamphetamine‐dependent adults 3 years after treatment. Drug and Alcohol Review, 29(1), 12-20.
This study examines the prevalence of psychiatric conditions in people who use methamphetamine (MA). The study’s methods were experimental, and its participants were 526 MA-dependent adults who took part in the MTP, a randomized, controlled trial of psychosocial treatments for MA dependence. Further demographics, such as race, are not specified by the study.
In this empirical trial, they underwent reassessment for psychosocial functioning and drug use a median of 3 years after starting psychosocial therapy for MA dependence. MA use was quantified as the number of months during which use occurred in the follow-up period, measured by the Life Experiences Timeline interview. According to the quantitative data gathered, 48.1% of the sample fit the criteria of mental disease other than a substance use disorder. The results showed that after therapy in MA users, this cohort has a higher prevalence of Axis I and II issues.